<DOC>
	<DOCNO>NCT02154347</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy KAD-1229 combination therapy insulin patient type 2 Diabetes Mellitus show inadequate glycemic control diet , insulin monotherapy , insulin oral hypoglycemic agent .</brief_summary>
	<brief_title>Post-marketing Clinical Trial KAD-1229 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Patients receive dietary therapy stable dose regimen insulin 8 week time observation term start Patients whose HbA1c time observation term start 7.5 % le 10.0 % Type 1 Diabetes Mellitus Patients serious diabetic complication serious complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>HbA1c</keyword>
</DOC>